Your session is about to expire
← Back to Search
Beta-blocker
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction (HFpEF-BB Trial)
N/A
Waitlist Available
Led By Kai Chen, MD,PhD
Research Sponsored by UConn Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and after 4 weeks of beta blocker discontinuation
Awards & highlights
No Placebo-Only Group
Summary
This trial will evaluate how well a heart medication works in 30 patients with heart failure.
Eligible Conditions
- Heart Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and after 4 weeks of beta blocker discontinuation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and after 4 weeks of beta blocker discontinuation
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in KCCQ-23 score
Secondary study objectives
6 minute walk test
Changes in biomarker
Changes in cardiac mechanics by echocardiography
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HFpEF patientsExperimental Treatment1 Intervention
HFpEF patient who are currently taking beta blockers
Find a Location
Who is running the clinical trial?
UConn HealthLead Sponsor
215 Previous Clinical Trials
60,691 Total Patients Enrolled
2 Trials studying Heart Failure
1,050 Patients Enrolled for Heart Failure
Kai Chen, MD,PhDPrincipal InvestigatorUConn Health